Primary Open Angle Glaucoma: Clinical Trials

75 completed, 34 unknown, 15 recruiting, 15 terminated. 60 Not applicable, 26 Phase 2, 15 Phase 4, 13 Phase 3, 9 Phase 1.

By phase and status

Phase	Trials	Status
Not applicable	60	Completed 24, Unknown 12, Recruiting 10, Terminated 7, Active not recruiting 4, Withdrawn 2, Suspended 1
Phase 2	26	Completed 17, Unknown 6, Active not recruiting 1, Enrolling by invitation 1, Terminated 1
Phase 4	15	Completed 10, Terminated 2, Unknown 2, Not yet recruiting 1
Phase 3	13	Completed 8, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Phase 1	9	Completed 5, Unknown 3, Enrolling by invitation 1
Early Phase 1	1	Unknown 1

Follow Primary Open Angle Glaucoma: new trials by email Literature Review of Primary Open Angle Glaucoma trials Research Report on Primary Open Angle Glaucoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma	Phase 1 / Phase 2	Enrolling by invitation	Stanford University	90	2026-09-10	2026-10-13
Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma Product DNN.31.19.026, COSOPT® - Ocular Hypertension, Primary Open Angle Glaucoma	Phase 3	Not yet recruiting	Ache Laboratorios Farmaceuticos S.A.	336	2026-06-01	2026-06-01
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group Microshunt XI - Primary Open Angle Glaucoma		Recruiting	Santen SAS	112	2026-03-19	2026-10-28
Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues physical activity, usual care - Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease	Not applicable	Recruiting	Cairo University	40	2026-03-15	2026-05-20
DSLT for Reducing Medication in Glaucoma Voyager DSLT - Primary Open Angle Glaucoma, Ocular Hypertension		Recruiting	The Eye Institute of West Florida	60	2026-02-10	2026-04-20
Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea lifetyle corrections and CPAP, CPAP - Primary Open Angle Glaucoma, Obstructive Sleep Apnea	Not applicable	Recruiting	Cairo University	40	2026-02-04	2026-03-03
Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma Hexiris Microinvasive Scleral Trephine (MIST) - Primary Open Angle Glaucoma	Not applicable	Recruiting	Hexiris Inc	25	2026-01-15	2026-01-22
OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma OMNI 3.0 Surgical System - Primary Open Angle Glaucoma	Not applicable	Active not recruiting	Sight Sciences, Inc.	25	2025-10-08	2026-10-19
Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma Progression Home IOP telemonitoring with smart phone-based intervention, Standard care and smart phone-based intervention - Glaucoma, Intraocular Pressure	Not applicable	Recruiting	The University of Hong Kong	142	2025-09-18	2026-09-03
Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane - Primary Open Angle Glaucoma	Phase 4	Not yet recruiting	Center for Sight Las Vegas	68	2025-07-15	2025-07-03
A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) Helix Surgical System - Primary Open Angle Glaucoma, Cataract	Not applicable	Active not recruiting	Sight Sciences, Inc.	25	2025-05-21	2026-07-07
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma Transcorneal electrical stimulation (TES) with the OkuStim 2 System - Glaucoma, Primary Open Angle Glaucoma	Not applicable	Recruiting	Okuvision GmbH	50	2025-04-02	2026-03-12
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma XEN63 Glaucoma Treatment System - Primary Open Angle Glaucoma	Phase 3	Recruiting	AbbVie	130	2025-02-11	2026-10-09
The Objective is to Evaluate the Anterior Chamber Angle After BANG Procedure, the Study Will Recruit 12 Patients Who Will Undergo Planned Goniectomy for Uncontrolled POAG, Anterior Segment OCT Scan Will Be Used to Evaluate the Anterior Chamber Postoperatively. Anterior segment optical coherence tomography - Primary Open Angle Glaucoma, Glaucoma		Unknown	Benha University	12	2024-11-01	2024-07-29
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication - Primary Open Angle Glaucoma	Phase 4	Terminated	Sight Sciences, Inc.	2	2024-08-21	2025-01-29
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation BD113vVLP - Primary Open Angle Glaucoma	Not applicable	Suspended	Shanghai BDgene Co., Ltd.	9	2024-06-10	2026-08-20
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy Minimally Invasive Micro Sclerostomy Device - Primary Open Angle Glaucoma, Open Angle Glaucoma	Not applicable	Unknown	Sanoculis Ltd	129	2024-06-01	2024-08-07
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population External Automatic Glaucoma Laser, Direct Selective Laser Trabeculoplasty - Primary Open Angle Glaucoma, Ocular Hypertension	Not applicable	Active not recruiting	BelkinVision	40	2024-03-11	2026-08-17
A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension TFC-003, COSOPT ophthalmic solution - Primary Open Angle Glaucoma, Ocular Hypertension	Phase 2	Unknown	Kukje Pharma	60	2024-02-01	2023-12-20
XEN Glaucoma Gel Stent Versus Trabeculectomy surgery - Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma	Not applicable	Recruiting	Prof. Dr. Herbert Reitsamer	196	2023-12-20	2025-06-03

Showing 20 of 157. Sign in to see all of them.

Narrower conditions

Glaucoma, Open-Angle (157)  ·  Ocular Hypertension (52)  ·  Glaucoma (39)  ·  Exfoliation Syndrome (11)  ·  Low Tension Glaucoma (10)  ·  Cataract (7)  ·  Glaucoma, Angle-Closure (3)  ·  Glaucoma, Neovascular (2)  ·  Patient Compliance (2)  ·  Sleep Apnea, Obstructive (2)  ·  Apnea (1)  ·  Blindness (1)  ·  Disease Progression (1)  ·  Hypertension (1)  ·  Motor Activity (1)

Broader conditions

Eye Diseases (157)  ·  Glaucoma (118)  ·  Ocular Hypertension (105)  ·  Iris Diseases (11)  ·  Optic Nerve Diseases (11)  ·  Uveal Diseases (11)  ·  Lens Diseases (7)  ·  Behavior (3)  ·  Nervous System Diseases (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Cardiovascular Diseases (2)  ·  Dyssomnias (2)  ·  Health Behavior (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Patient Acceptance of Health Care (2)

Interventions

Latanoprost (16)  ·  Cataract Extraction (8)  ·  Timolol (7)  ·  Travoprost (6)  ·  Trabeculectomy (5)  ·  tafluprost (4)  ·  Duotrav (3)  ·  Lubricant Eye Drops (3)  ·  Mitomycin (3)  ·  Phacoemulsification (3)  ·  dorzolamide (3)  ·  Bimatoprost (2)  ·  Brimonidine Tartrate (2)  ·  Ophthalmic Solutions (2)  ·  Prostaglandins (2)

Sponsors

Alcon Research (6)  ·  Sensimed AG (6)  ·  Ivantis, Inc. (5)  ·  Cairo University (4)  ·  Medical University of Vienna (4)  ·  Wills Eye (4)  ·  Duke University (3)  ·  InnFocus Inc. (3)  ·  Laboratorios Sophia S.A de C.V. (3)  ·  Nova Eye, Inc. (3)  ·  Sight Sciences, Inc. (3)  ·  University of California, San Diego (3)  ·  Altheos, Inc. (2)  ·  Aristotle University Of Thessaloniki (2)  ·  Bausch & Lomb Incorporated (2)

Countries

United States (57)  ·  Germany (13)  ·  Italy (12)  ·  United Kingdom (11)  ·  Austria (9)  ·  France (8)  ·  Spain (8)  ·  Canada (6)  ·  China (6)  ·  Egypt (6)  ·  Mexico (5)  ·  Netherlands (5)  ·  South Korea (5)  ·  Switzerland (5)  ·  Greece (4)

Top investigators

Ali MA Ismail, lecturer (2)  ·  Alon Harris, PhD (2)  ·  Anselm G Juenemann, Prof. (2)  ·  Michele Vetrugno, MD (2)  ·  Shamil Patel, MD, MBA (2)  ·  Aakriti G. Shukla, MD (1)  ·  Alan Crandall, MD (1)  ·  Alexandra Papp, MD (1)  ·  Ali Ismail, lecturer (1)  ·  Andrew G. Iwach, M.D. (1)  ·  Anna Grau (1)  ·  Anne Rubin (1)

Results publications

PMID 22427577, PMID 23557744, PMID 23746612, PMID 25358735, PMID 27117781, PMID 28551166, PMID 37793935, PMID 39663002, PMID 40408035, PMID 10201583, PMID 10206571, PMID 10366081, PMID 10549639, PMID 10664926, PMID 11006239, PMID 11165541, PMID 11235540, PMID 12049574, PMID 12126947, PMID 12383810, PMID 12395089, PMID 12511365, PMID 12640353, PMID 12809158, PMID 12809160, PMID 1454314, PMID 15126151, PMID 15197057, PMID 15223803, PMID 15277482, PMID 15326133, PMID 15488786, PMID 15555526, PMID 15652827, PMID 15691551, PMID 15980233, PMID 16123421, PMID 16175374, PMID 16249495, PMID 16249960, PMID 16406535, PMID 16413223, PMID 16767190, PMID 16908813, PMID 17196589, PMID 17532502, PMID 17700284, PMID 17980433, PMID 17997485, PMID 18385063

NIH funding

2014 (1), K23EY022659 (1), K23EY026098 (1), P30AG022838 (1), R01EY023704 (1), R01EY026574 (1), R01EY027510 (1)